14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs ABCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.12 (27.6x Forward P/E, -1550.0% operating margin).
Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZBIO vs ABCL Key Questions & Quantitative Answers
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.12 (27.6x Forward P/E, -1550.0% operating margin). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABCL leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ZBIO cumulative revenue shifted -80.0% while ABCL shifted +700.0%. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.
ABCL screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus ABCL (-17.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, ABCL carries 84.0% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.30β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.